NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.
With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.
FDA approves Unloxcyt, a new drug by Checkpoint Therapeutics, for the treatment of advanced and metastatic cutaneous squamous cell carcinoma, showing promising results in clinical studies.
Health care professionals welcome the FTC's new rule banning noncompete agreements but are concerned it may not protect those in nonprofit health care settings, potentially impacting most of the nation's medical professionals.